PEARL: Fremanezumab effectiveness in chronic or episodic migraine.

• Research type

  Research Study

• Full title

  Pan-European prospective observational study of fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World: PEARL study

• IRAS ID

  281137

• Contact name

  Paul Dorman

• Contact email

  p.dorman@nhs.net

• Sponsor organisation

  Teva Pharmaceuticals

• Duration of Study in the UK

  3 years, 6 months, 0 days

• Research summary

  The study is a phase 4 Pan European study which seeks to evaluate the effectiveness of fremanezumab given to adults who have chronic migraine (CM) or episodic migraine (EM) and suffer at least 4 migraine days per month. The study will also review the number of patients reaching at least 50% reduction in the monthly average number of migraine days during the 6-month period after the first dose of fremanezumab. Patients will maintain a daily headache diary as part of their routine disease
  management at the discretion of their treating physician; these data will inform the outcomes and impact of fremanezumab in real-world clinical practice.The study is planned to be conducted in approximately 100 centers in approximately 11 European countries.

• REC name

  London - Bromley Research Ethics Committee

• REC reference

  20/PR/0005

• Date of REC Opinion

  22 Jul 2020

• REC opinion

  Further Information Favourable Opinion